CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
人工智能在癌症免疫治疗中的应用：提升疗效与安全性的前沿综述
英文原题：Applications of artificial intelligence in cancer immunotherapy: a frontier review on enhancing treatment efficacy and safety.
查看英文原题
Applications of artificial intelligence in cancer immunotherapy: a frontier review on enhancing treatment efficacy and safety.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症免疫治疗是肿瘤学的重大突破，尤其是免疫检查点抑制剂（ICIs）和 CAR-T 细胞疗法。尽管疗效有所改善，但免疫相关不良事件（irAEs）和治疗耐药等挑战限制了临床应用。人工智能（AI）为解决这些障碍提供了新机遇，包括靶点识别、疗效预测、毒性监测和个体化治疗设计。本综述重点介绍 AI 在生物标志物发现、安全性评估、基因编辑、纳米技术和微生物组调控方面应用的最新进展，并整合了临床和临床前研究的证据。我们还讨论了 AI 应用于癌症免疫治疗的未来方向和挑战，旨在支持进一步研究和临床转化。
展开英文摘要原文
Cancer immunotherapy represents a major breakthrough in oncology, particularly with immune checkpoint inhibitors (ICIs) and CAR-T cell therapies. Despite improved outcomes, challenges such as immune-related adverse events (irAEs) and treatment resistance limit clinical use.
Artificial intelligence (AI) offers new opportunities to address these barriers, including target identification, efficacy prediction, toxicity monitoring, and personalized treatment design. This review highlights recent advances in AI applications for biomarker discovery, safety evaluation, gene editing, nanotechnology, and microbiome modulation, integrating evidence from clinical and preclinical studies.
We also discuss future directions and challenges in applying AI to cancer immunotherapy, aiming to support further research and clinical translation.
论文信息
- 作者
- Liu J、Fu R、Su Y、Li Z、Huang X、Wang Q、Shi Z、Wei S
- 第一作者单位
- The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.China
- 通讯作者单位
- Department of Gastrointestinal Surgery, Suining Central Hospital, Suining, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 41246300 · DOI 10.3389/fimmu.2025.1676112
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →